NVTAQ — InVitae Share Price
0.000.00%
Last trade - 00:00- $0.11m
- $1.10bn
- $516.30m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -394.88% | ||
| Return on Equity | n/a | ||
| Operating Margin | -308.88% | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 147.7 | 216.82 | 279.6 | 460.45 | 516.3 | 472.7 | 476.3 | 49.9% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Invitae Corporation is a medical genetics company. The Company is engaged in delivering genetic testing services, digital health solutions, and health data services that support a lifetime of patient care and improved outcomes. It offers genetic testing across multiple clinical areas, including hereditary cancer, precision oncology, women's health, rare diseases and pharmacogenomics. It applies proprietary design, process automation, robotics and bioinformatics software solutions to expand the use and impact of genetic information in sample processing and complex variant interpretation, allowing medical interpretation at scale. The Company also utilizes digital health solutions to improve ease-of-use and to deliver actionable information about risk, prevention, treatment, and monitoring. The Company has served over 3.6 million patients, and over 2.2 million of those patients have made their information available for data sharing.
Directors
- Eric Aguiar NEC (59)
- Sean George PRE (47)
- Yafei Wen CFO (49)
- Kenneth Knight COO (61)
- Robert Werner CAO (47)
- Thomas Brida GCN (50)
- Robert Nussbaum OTH (71)
- Katherine Stueland OTH (45)
- Karthik Suri OTH
- Geoffrey Crouse IND (50)
- Christine Gorjanc IND (64)
- Kimber Lockhart IND (34)
- Chitra Nayak IND (58)
- Last Annual
- December 31st, 2022
- Last Interim
- September 30th, 2023
- Incorporated
- January 13th, 2010
- Public Since
- February 12th, 2015
- No. of Shareholders
- 276
- No. of Employees
- 1,700
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 286,492,840
- Address
- 1400 16Th Street, SAN FRANCISCO, 94103
- Web
- https://www.invitae.com
- Phone
- +1 4153747782
- Auditors
- Ernst & Young LLP
Upcoming Events for NVTAQ
Q2 2024 Invitae Corp Earnings Release
Q3 2024 Invitae Corp Earnings Release
Similar to NVTAQ
Acorda Therapeutics
Pink Sheets on Nasdaq
Actavia Life Sciences
Pink Sheets on Nasdaq
Acura Pharmaceuticals
Pink Sheets on Nasdaq
Adhera Therapeutics
Pink Sheets on Nasdaq
Ramoil Management
Pink Sheets on Nasdaq
FAQ
What is the InVitae share price?
As of Today at 21:23 UTC, shares in InVitae are trading at $0.00. This share price information is delayed by 15 minutes.
How has the InVitae share price performed this year?
Shares in InVitae last closed at $0.00 and the price had moved by -99.73% over the past 365 days. In terms of relative price strength the InVitae share price has underperformed the S&P500 Index by -99.78% over the past year.
What are the analyst and broker recommendations for InVitae?
The overall consensus recommendation for InVitae is Sell. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the InVitae dividend yield?
InVitae does not currently pay a dividend.
Does InVitae pay a dividend?
InVitae does not currently pay a dividend.
When does InVitae next pay dividends?
InVitae does not currently pay a dividend.
How do I buy InVitae shares?
To buy shares in InVitae you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of InVitae?
As of the previous close price of $0.00, shares in InVitae had a market capitalisation of $0.86m.
Where are InVitae shares listed?
Here are the trading details for InVitae:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: NVTAQ
What kind of share is InVitae?
Based on an overall assessment of its quality, value and momentum InVitae is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a InVitae share price forecast for 2024?
The analyst consensus target price for shares in InVitae is $0.30. That is 9900% above the last closing price of $0.00.
Analysts covering InVitae currently have a consensus Earnings Per Share (EPS) forecast of -$1.06 for the next financial year.
Find out moreWhat is the trend in the InVitae share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like InVitae. Over the past six months, its share price has underperformed the S&P500 Index by -99.62%.
As of the last closing price of $0.00, shares in InVitae were trading -99.06% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the InVitae PE Ratio?
The InVitae PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of InVitae?
InVitae's management team is headed by:
- Eric Aguiar - NEC
- Sean George - PRE
- Yafei Wen - CFO
- Kenneth Knight - COO
- Robert Werner - CAO
- Thomas Brida - GCN
- Robert Nussbaum - OTH
- Katherine Stueland - OTH
- Karthik Suri - OTH
- Geoffrey Crouse - IND
- Christine Gorjanc - IND
- Kimber Lockhart - IND
- Chitra Nayak - IND